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a b s t r a c t
Introduction: Accumulating evidence suggests that inflammation plays an important role in the develop-
ment of acute cerebrovascular disease. The aim of this study is to evaluate the predictive value of a series
of candidate serum immuno-inflammatory and thrombotic/fibrinolitic molecules towards diagnosis of
acute ischemic stroke.
Materials and methods: We enrolled 120 consecutive patients with a diagnosis of acute ischemic stroke and
123 consecutive hospitalized control patients without a diagnosis of acute ischemic stroke. We evaluated
plasma levels of IL-1, TNF-, IL-6 and IL-10, E-selectin, P-selectin, sICAM-1 and sVCAM-1 as markers of
immuno-inflammatory activation, vWF plasma levels as a marker of endothelial dysfunction, TPA antigen
and PAI-1 plasma levels as a marker of a prothrombotic state.
Results: TNF-, PAI-1 and TPA on bivariate logistic regression were highly correlated to stroke diagnosis.
Among the other variables maintained in the final model IL, Selectin E, were significantly associated
with acute ischemic stroke diagnosis, whereas IL-6, VICAM-1, ICAM-1 and neutrophil percentage showed
only a slight or no association with stroke diagnosis. Furthermore, only the continuous values of TNF-,
PAI-1 and TPA showed a significant predictive value and likelihood ratio, with an area under the ROC curve
of 98.6%, 97.1% and 99.9%, respectively.
Discussion: Our findings could suggest the high diagnostic power of these immuno-inflammatory and
thrombotic/fibrinolytic variables in patients with acute ischemic stroke. Although our results are encour-
aging, additional studies are needed to establish the validity of this approach.
© 2008 Elsevier Ireland Ltd. All rights reserved.
1. Introduction
Accumulating evidence suggests that inflammation plays an
important role in the development of cardiovascular and cere-
brovascular disease [1,2]. Over the past few years has been stressed
the role of inflammation in the pathophysiology of acute brain
ischemia and how most inflammatory events are mediated by
cytokines, small glycoproteins expressed by many cell types in
response to acute cerebral ischemia [3,4]. Recently our group [5]
showed that stroke patients, compared to controls, have signifi-
cantly higher median plasma levels of some cytokines, adhesion
molecules and selectins until 72 h after onset of symptoms. The
central role of inflammation, expressed by cytokine cascade in
the pathogenesis of neuronal ischemic damage, could suggest
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a possible diagnostic role of candidate serum markers of this
immuno-inflammatory activation. In fact, the absence of widely
available and sensitive diagnostic tests for acute cerebral ischemia
remain, at present, a problem in the diagnosis and management
of stroke. Unlike acute coronary syndromes and congestive heart
failure with the myocardial isoform of creatine phosphokinase,
troponin and B-type natriuretic peptide, there is no single bio-
chemical diagnostic marker available for ischemic stroke that is
sufficiently sensitive and specific. To date, most clinical studies
concerning the evaluation of the immuno-inflammatory profile of
patients with ischemic stroke have been limited by low numbers
of patients enrolled and by the fact that no single biochemical
marker has been demonstrated to possess the requisite sensitiv-
ity and specificity to allow it to be used as a diagnostic marker.
Recently Lynch et al. [6] examined the feasibility of developing a
diagnostic panel of biochemical markers of cerebral ischemia, and
reported that a panel of biochemical markers comprising S 100,
matrix metalloproteinase-9, vascular cell adhesion molecule and
von Willebrand factor may be helpful in identifying stroke patients
in the prehospital setting.
0021-9150/$ – see front matter © 2008 Elsevier Ireland Ltd. All rights reserved.
doi:10.1016/j.atherosclerosis.2008.06.030
Author's personal copy
504 A. Tuttolomondo et al. / Atherosclerosis 203 (2009) 503–508
Taking into account the complexity of the brain ischemic cas-
cade mechanisms involving immuno-inflammatory, thrombotic
and fibrinolytic pathways, the aim of this study is to evaluate the
predictive value of some candidate serum immuno-inflammatory
and thrombotic/fibrinolytic molecules for acute ischemic stroke
diagnosis.
2. Materials and methods
We enrolled 120 consecutive patients with a diagnosis of acute
ischemic stroke admitted to the Internal Medicine Department at
the University of Palermo between November 2002 and January
2005, and 123 hospitalized control patients without a diagnosis
of acute ischemic stroke. Control subjects were patients admitted,
in the same period, to our Internal Medicine Department for any
cause other than acute cardiovascular and cerebrovascular events
or exclusion criteria (see below).
Stroke was defined by focal neurological signs or symptoms
thought to be of vascular origin that persisted for >24 h confirmed
by brain CT and/or MRI in baseline conditions and brain CT with
contrast medium after 48–72 h [7].
In order to match patients with acute ischemic stroke and
controls also for cardiovascular risk and previous cardiovascular
morbidity, controls were included if they had vascular risk factors
or a history of myocardial infarction or cerebrovascular disease or
peripheral vascular disease, but they were excluded if they had
either current or recent (until 6 months) cerebrovascular disease
or one of the exclusion criteria (see above).
Cardiovascular risk factors were evaluated for both cases and
controls on the basis of the criteria shown below. Hypercholes-
terolemia was defined as the presence of total cholesterol blood
levels ≥200 mg/dL. Hypertension was defined as present if sub-
jects had been previously diagnosed according the World Health
Organization/International Society of Hypertension guidelines and
were routinely receiving antihypertensive therapy. Patients were
defined as type 2 diabetics if they had known diabetes treated by
diet, oral hypoglycaemic drugs or insulin before stroke Previous
coronary artery disease was determined on the basis of a history of
physician-diagnosed angina, myocardial infarction, or any previous
revascularization procedure assessed by a questionnaire.
Previous cerebrovascular disease (TIA/ischemic stroke) was
assessed by history, specific neurologic examination executed by
specialists, and hospital or radiological (brain computed tomog-
raphy or brain magnetic resonance) records of definite previous
stroke.
Subjects were classified as having previous peripheral artery
disease (PAD) when they had a history of ABI <0.9 and/or of inter-
mittens claudicatio or of critical limb ischemia or when they had
undergone a peripheral arterial bypass or amputation.
The study protocol was approved by the local ethics committee,
and all participants gave written informed consent.
Every subject with ischemic stroke was matched for age (±3
years), sex, and cardiovascular risk factor prevalence and previous
vascular events with one control subject.
Patients with inflammatory or infectious diseases, cancer,
hematological diseases and severe renal or liver failure, as well as
those who were under treatment with anti-inflammatory drugs,
were excluded.
The type of acute ischemic stroke was classified according to the
TOAST classification [6]: (1) large artery atherosclerosis (LAAS); (2)
cardioembolic infarct (CEI); (3) lacunar infarct (LAC); (4) stroke of
other determined etiology (ODE); (5) stroke of undetermined eti-
ology (UDE). All the ischemic stroke patients underwent: medical
history with recording of potential stroke risk factors, blood and
coagulation tests, 12-lead ECG, 24 h electrocardiography monitor-
ing, transthoracic echocardiography, carotid ultrasound, brain CT
or MRI at admission.
Blood samples were obtained in the non-fasting state. After
10 min of rest in the supine position, 35 mL blood was collected
from the antecubital vein. EDTA-anticoagulated peripheral blood
was drawn from each patient within 72 h of onset of symptoms.
Serum and plasma were immediately separated by centrifugation
and stored in aliquots at −80 ◦C until analysis.
We evaluated plasma levels of IL-1, TNF-, IL-6 and IL-
10, E-selectin, P-selectin, sICAM-1 and sVCAM-1 as markers of
immuno-inflammatory activation, vWF plasma levels as a marker
of endothelial dysfunction, TPA antigen and PAI-1 plasma levels as
a marker of a thrombotic/fibrinolytic state.
We chose to evaluate these biomarkers because acute ischemic
stroke has been associated with serum elevations of a series of
immuno-inflammatory variables such as TNF-, interleukin-6 (IL-
6) and other cytokines, selectins and adhesion molecules [7–10]
and of markers of impaired hemostasis and thrombosis [11–13].
IL-1, TNF-, IL-6 and IL-10 and vWF antigen were measured
using a sandwich ELISA (Human IL-1, TNF-, IL-6 and IL-10
Quantikine, R&D Systems (VWF ELISA kitdurian, Instrumentation
Laboratory, Milano, Italy); VCAM-1, ICAM-1, E-selectin, P-selectin,
PAI-1 and TPA-antigen were measured by commercial bioim-
munoassay (Human sICAM-1, sVCAM-I, sE-selectin and sP-selectin
Parameter, Quantikine, R&D Systems, Gentaur AssayMax Human
Plasminogen Activator Inhibitor-1 (PAI-1) ELISA Kit, Gentaur Assay-
Max Tissue Plasminogen Activator (TPA) ELISA Kit).
The minimum detectable concentrations for the diagnostic tests
are: TNF alpha: 1.6 pg/mL, IL-1: <1 pg/mL, IL-6: <0.70 pg/mL, IL-10:
>3.9 pg/mL, ICAM-1: <0.35 ng/mL, VCAM-1: 0.6 ng/mL, E-Selectin:
<0.1 ng/mL, P-Selectin: <0.5 ng/mL, vWF: 1.0%, TPA: 0.3 pg/mL, PAI-
1: <50 pg/mL.
Intraassay and interassay coefficients of variation were: TNF
alpha: 4.2% and 4.6%; IL-1: 3.3% and 4.2%; IL-6: 1.6% and 3.3%;
IL-10: 4.3% and 7.5%; ICAM-1: 4.8% and 6.1%; VCAM-1: 3.5% and
7.7%; E-Selectin: 4.8% and 5.7%; P-Selectin: 4.9% and 8.8%; vWF: 5%
and 10%; TPA: 4.8% and 5%; PAI-1: 5.7% and 8.3%.
3. Statistical analysis
Data are reported as median (lower quartile ↔ upper
quartile). Comparisons between groups were performed by
Mann–Whitney U-test. The Kruskal–Wallis test was performed
as non-parametric analysis of variance for multiple comparisons,
and the Conover–Inman procedure was used as post hoc test to
make all possible pair-wise comparisons between groups. The
Wilcoxon signed ranks test statistic was performed to compare
control to baseline data. Pearson chi-square was computed for
categorical variables. A two-tailed p value <0.5 was considered
statistically significant. To investigate relationships between
predictor variables and stroke, in the whole study sample, logistic
regression technique was performed and stroke was considered
the outcome variable. First, a bivariate logistic regression analysis
was performed to individuate relationships between predictors
and the outcome variable (Stroke). TNF-, TPA and PAI-1 are
presented only as bivariate analysis by a high grade of correlation
with the outcome variable. These variables were excluded a priori
from the final model. TNF- was transformed into log (base 10)
values to run logistic regression analysis. Then, variable selections
for the final model and linear relationships between outcome
and continuous predictors were investigated as suggested by
Hosmer and Lemeshow [14]. Odds ratios and their 95% confidence
intervals were computed. A bootstrap procedure may be used
to cross-validate confidence intervals calculated for odds ratios
Author's personal copy
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Table 1
General and clinical characteristics of stroke patients and controls
Variable Stroke pts (n: 120) Controls (n: 123) p
Age (years) 72 (64–82.5) 69 (65–83) 0.749
Glucose blood levels (mg/dL) 155.5 (99–233) 139 (87.5–193.5) 0.001
Cholesterol blood levels (mg/dL) 232 (199–260) 200 (178–225) <0.001
Triglycerides blood levels 187.5 (140.75–211.75) 154 (98–200) 0.007
White body cells (WBC) (per mm3) 8000 (6700–10,000) 6400 (5500–8800) <0.001
Neutrophils (%) 5780 (4071–8000) 3843 (336–6320) <0.001
Sex (M/F) 68/52 55/68 0.062
Diabetes (n/%) 50 (41.7) 59 (48%) 0.363
Hypertension (n/%) 74 (61.7%) 63 (51.2%) 0.101
Previous stroke (n/%) 39 (32.5) 37 (30.08) 0.75
CAD (n/%) 25 (20.8) 24 (19.5) 0.46
PAD (n/%) 14 (11.6) 17 (13.8) 0.23
Data are expressed as median and interquartile (lower and upper quartile). Demographic and anamnestic data are expressed as no. (percentage).
Table 2
Immuno-inflammatory and thrombotic/phybrinolytic variables in stroke subjects vs. controls
Variable Stroke patients Controls p
n 120 123
IL-1 (pg/mL) 9 (4–11) 3 (2–5) <0.001
IL-6 (pg/mL) 11 (6–30) 9 (2.9–18) <0.001
TNF- (pg/mL) 31.5 (10.25–41) 3.7 (1.1–4.3) <0.001
E-selectin n/mL) 2.25 (2.0–4.0) 2 (1–2) <0.001
P-selectin (ng/mL) 4 (2–6.3) 3,1 (2.1–4) 0.004
VICAM (ng/mL) 20 (15.1–23) 14 (13–17) <0.001
ICAM (ng/mL) 20.8 (16.2–24) 15.9 (12–18.1) <0.001
IL-10 (pg/mL) 3.75 (2–9) 4 (2–10) 0.433
vWF (ng/mL) 10 (6–10) 4 (3–8) 0.0001
PAI-1 (pg/mL) 142 (109.5–175) 21 (12–26) <0.001
TPA (pg/mL) 24 (15.75–36) 74 (59–98) <0.001
Data are expressed as median and interquartile (lower and upper quartile). Demographic and anamnestic data are expressed as no. (percentage). TNF-: tumor necrosis
factor ; IL-1: interleukin-1; IL-6: interleukin-6; IL-10: interleukin-10; ICAM-1: intercellular adhesion molecule-1; V-CAM-1: vascular cell adhesion molecule-1; vWF:
von Willebrand factor; TPA: tissue plasminogen activator; PAI-1: plasminogen activator inhibitor-1.
derived from fitted logistic models [15]. The bootstrap confidence
intervals used are the ‘bias-corrected’ type. To evaluate the pre-
dictive role of different values of some immuno-inflammatory
variables, we evaluated sensibility, specificity, likelihood ratio and
receiver-operating characteristics (ROC) with their area under the
curve (AUC) were constructed.
According to sample size calculation, 110 enrolled sub-
jects were needed to detect a minimal relative prognostic
risk of 2.1 for patients with different levels of cytokines and
thrombotic–fibrinolytic markers with an alfa error of 0.05 and a
power of 0.80.
4. Results
General characteristics of patients enrolled in the
study are reported in Table 1. Immuno-inflammatory and
thrombotic–fibrinolytic variables are reported in Table 2.
Among stroke patients, according to TOAST Classification, 50
were classified as LAAS, 46 as lacunar, 20 as CEI and 4 as ODE (see
Table 3).
Immuno-inflammatory variables of patients with acute
ischemic stroke and of controls are shown in Table 2. Stroke
patients compared to controls showed significantly higher median
Table 3
Immuno-inflammatory markers in patients with ischemic stroke in relation of TOAST subtypes
Variable LAAS Lacunar CEI ODE p
n 50 46 20 4
TNF- (pg/mL) 27.5 (13.4–40.5) 19.4 (9–23) 38.5 (22.2–46) 29 (10.4–39.0) <0.0001
IL-6 (pg/mL) 8 (4–12) 4 (2–9) 11 (5,5–19) 7 (4.5–12.5) 0.0029
IL-1 (pg/mL) 9 (5–10.5) 6 (10–3) 11.5 (8–13) 3.5 (2–7) <0.0001
ICAM-1 (ng/mL) 20.8 (15.9–24) 19.91 (15–23) 19.52 (18.55–23) 17.25 (14.95– 18.8) 0.56
VCAM-1 (pg/mL) 20 (15–24) 17 (20–15) 20 (15.7–26) 17.5 (14–19) 0.53
E-selectin (ng/mL) 3 (2–4) 2 (2–4) 2.75 (2–3.5) 2.5 (1.3–3) 0.801
P-selectin (ng/mL) 4.95 (2–6.5) 4 (2.4–6) 3,4 (1.46–6.43) 1.75 (1.05–5.2) 0.49
vWF (ng/mL) 8 (6–10) 6 (3–8) 10 (5–12) 5 (4–9) 0.05
PAI–1 (pg/mL) 134 (98–168) 155 (108.25–172) 162 (123–187) 122 (111–187) 0.61
TPA (pg/mL) 24 (14–36) 28 (20–38) 22 (17–23) 20 (18–27) 0.85
Data are expressed as median and interquartile (lower and upper quartile). TNF-: tumor necrosis factor ; IL-1: interleukin-1; IL-6: interleukin-6; IL-10: interleukin-10;
ICAM-1: intercellular adhesion molecule-1; V-CAM-1: vascular cell adhesion molecule-1; vWF: von Willebrand factor; TPA: tissue plasminogen activator; PAI-1: plasminogen
activator.
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Table 4
Infarct site at neuroimaging findings (brain CT or MRI) in relation of TOAST diagnostic subtype
Large artery atherosclerosis (n: 50) Cardioembolic strokes (n: 20) Lacunar strokes (n: 46)
Neuroimaging findings
Cortical 31 (62%) 16 (80%) 8 (17.3%)
Subcortical 19 (38%) 4 (20%) 28 (60.8%)
Internal capsula 10 (52.6%) 4 (100%) 10 (35.7%)
Thalamus 4 (21%) 0 7 (25%)
Basal ganglia 5 (26.3%) 0 5 (21.7%)
Pons 0 0 2 (7.1%)
Corona radiata 0 0 4 (14.2%)
No lesion CT or MRI detectable 0 0 10 (21%)
Table 5






TNF-: tumor necrosis factor ; PAI-1: plasminogen activator inhibitor-1; TPA: tis-
sue plasminogen activator.
plasma levels of IL1-, IL-6, TNF-, E-Selectin, P-Selectin, V-CAM-1
and ICAM-1.
Immuno-inflammatory variables in relation to TOAST stroke
subtypes are shown in Table 3.
Patients with ischemic stroke classified as cardioembolic (CEI)
showed, compared to other subtypes, significantly higher median
plasma levels of TNF- [38.5 (22.2–46); p < 0.0001], IL-6 [11
(5.5–19). p = 0.0029], IL-1 [11.5 (8–13); p < 0.0001], whereas
plasma levels of Von Willebrand factor in patients with cardioem-
bolic subtype were higher compared to other subtypes but were
only near statistical significance [10 (5–12) (p = 0.0053) (Table 3).
Furthermore, stroke patients classified as lacunar showed, com-
pared to other subtypes, significantly lower median plasma levels
of TNF- [19.4 (9–23) pg/mL; p < 0.0001]; IL-6 [(4 (2–9) pg/mL;
p = 0.0029)], IL-1 [6 (10–3) p < 0.0001)], whereas plasma levels of
Von Willebrand factor in [6 (3–8) ng/mL] patients with lacunar sub-
type were lower compared to other subtypes, but were only nearly
significant statistically (Table 3).
Infarct sites at neuroimaging findings (brain CT or MRI) in rela-
tion to TOAST diagnostic subtype are shown in Table 4.
Among the clinical, laboratory and immuno-inflammatory
variables analyzed in our patients with acute ischemic stroke,
TNF-, PAI-1 and TPA on bivariate logistic regression were
highly correlated to stroke diagnosis. These variables include
one immuno-inflammatory variable (TNF-) (P < 0.0001) and
two thrombotic–fibrinolytic variables (PAI-1 and TPA) (p = 0.004;
p < 0.0001) (Table 5).
Among the other variables maintained in the final model
after exclusion of TNF-, PAI-1 and TPA, IL1 (OR: 1.77; 95% CI:
Table 6
Multivariate logistic regression about relationship between clinical and immuno-
inflammatory variables and outcome variable (stroke)
Odds ratio 95% CI b p
IL-1 1.79 1.51–2.32 0.57 <0.0001
IL6 1.04 0.95–1.11 0.009 0.75
E-selectin 1.98 1.48–2.68 0.67 0.0001
VICAM-1 1.19 1.04–1.32 0.16 0.009
ICAM-1-1 1.24 1.12–1,39 0.25 0.0001
vWF 1.85 1.49–2.48 0.62 0.0001
Neut 1.04 0.89–1.10 0.02 0.0028
Previous stroke 0.89 0.75–1.02 0.004 0.68
Previous CAD 0.77 0.63–0.95 0.003 0.80
Previous PAD 0.78 0.55–0.95 0.005 0.88
IL-1: interleukin-1-; IL6: interleukin-6; V-CAM-1: vascular cell adhesion
molecule-1; ICAM-1: intercellular adhesion molecule-1; vWF: von Willebrand fac-
tor; neut: neutrophil count. CAD: coronary artery disease; PAD: peripheral artery
disease.
1.41–2.22), Selectin-E (OR: 1.96; 95% CI: 1.38–2) vWF (OR: 1.83; 95%
CI: 1.41–2.38), were significantly associated with acute ischemic
stroke diagnosis, whereas IL-6, VICAM-1, ICAM-1 and neutrophil
percentage showed only a slight or no association with stroke
diagnosis (see Table 6). Previous stroke, CAD and PAD were not
associated with acute ischemic stroke diagnosis.
To provide a further demonstration of diagnostic utility for the
three markers that at bivariate analysis showed the highest corre-
lation with stroke diagnosis we developed a multivariable logistic
regression model, again as described above. The continuous values
of TNF-, PAI-1 and TPA showed a significant positive predictive
value (PPV), likelihood ratio (see Table 7), with an area under the
ROC curve of 98.6%, 97.1% and 99.9%, respectively (see Table 7).
5. Discussion
The aim of the present study was to assess the potential diag-
nostic utility of blood-borne protein biomarkers in predicting acute
stroke within 72 h of symptom onset.
We showed that one immuno-inflammatory variable (TNF-)
and two thrombotic/fibrinolytic (PAI-1 and TPA) variables were
significantly associated with stroke diagnosis.
Table 7
Diagnostic power of TNF-, PAI-1 and TPA
TNF- TPA PAI-1
Sensitivity (%) 93.33 8.67 99.17
Specificity (%) 96.75 86.99 99.19
PPV (%) 96.55 86.67 99.17
NPV (%) 93.7 86.99 99.19
LR (+ve) (95% CI) 28.7 (11.55–73.46) 6.662 (4.28–10.66) 121.975 (22.22–690.31)
LR (−ve) (95% CI) 0.068 (0.035–0.130) 0.153 (0.095–0.237) 0.008 (0.001–0.0460)
‘Near’ cut-off at max (sens + spec) 0.73 0.23 0.18
Area under ROC curve 0.986 0.971 0.999
PPV: positive predictive value; NPV negative predictive value; LR (+ve): positive likelihood ratio; LR (−ve): negative likelihood ratio; ROC curve: receiver operating characteristic
curve.
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Pathophysiology of neuronal damage in ischemic stroke is based
on a ischemic cascade involving inflammatory mechanisms with
cytokine activation, adhesion molecule and selectin involvement,
endothelial dyfunction and prothrombotic state. Knowledge of
the molecules participating in this pathogenic cascade causing
neuronal damage probably represents a chance to recognize pos-
sible serum markers of ischemic stroke useful to a diagnostic
algorithm of acute ischemic stroke. Increases of the proinflamma-
tory cytokines interleukin-1, IL-6 and TNF- have been detected
in the ischemic cortex 1 h after middle cerebral artery (MCA)
occlusion in experimental models of brain ischemia [8], and sev-
eral studies have reported elevations of these proinflammatory
cytokines in peripheral blood as well as in cerebrospinal fluid in
patients with ischemic stroke [15–20]. Nevertheless, pathogen-
esis of brain ischemia involves both immuno-inflammatory and
thrombotic mechanisms, so a good diagnostic panel for ischemic
stroke should include a representative biomarker of both these
pathogenic aspects. On this basis, in addition to cytokines, adhe-
sion molecules and selectins we also evaluated TPA/PAI plasma
levels and vWF plasma levels as marker of thrombotic/fibrinolytic
mechanisms and endothelial dysfunction in order to encompass
the three main aspects of brain ischemia pathogenesis: endothelial
dysfunction, thrombosis and inflammation.
In our study TNF-, PAI-1 and TPA were significantly associated
with ischemic stroke diagnosis.
Plasminogen activator inhibitor type 1 (PAI-1), which forms a
complex with tissue-type plasminogen activator (tPA), is a strong
inhibitor of fibrinolysis [21]. Until recently, PAI-1 was best known
for its antifibrinolytic properties. Nevertheless, Hoekstra et al. [22]
reported that elevated plasma PAI-1 is a strong risk indicator for
stroke at old age [21–27].
The mechanism that relates plasminogen activation to cere-
brovascular disease probably reflects a non-fibrinolytic function of
plasmin. Increased plasminogen activation may lead to increased
laminin degradation in extracellular brain tissue and, hence, a
reduced brain resistance to ischemic damage [28]. Nevertheless,
a possible role of PAI-1 as acute phase molecule is also plausible
[29].
A diagnostic marker of ischemic cerebral cascade could also be
useful to monitor clinical course and the possible clinical wors-
ening of patients with ischemic stroke. Quickly distinguishing
stroke from non-stroke represents a more intriguing possibil-
ity to apply to dubious cases prior to the imaging techniques
as brain CT or MRI even in the absence of a clear neurological
symptomatology.
In our study we have tested the possible predictive power of
a series of molecules involved in the inflammatory mechanism
of neuronal ischemic damage. Although their clinical applicability
could appear unrealistic for the healthcare expenditure, our find-
ing underlines the diagnostic role of TNF-, PAI-1 and TPA and this
finding could suggest to limit to these three immuno-inflammatory
and thrombotic/fibrinolytic markers as a possible employment in
acute setting.
Possible limitations of the study could be the fact that we have
not evaluated neurobiochemical markers such as S100B, NSE or glial
fibrillary acidic protein (GFAPI). S100B, however, is expressed not
only in brain tissue but also in a variety of other cell types, under
both physiological and pathological conditions. Expression of pro-
tein S-100 has been observed in white and brown fat, skin and
skeletal muscle tissue, melanoma or glioblastoma cells [30–32].
Moreover, S-100B expression in the latter conditions was far below
the activity measured after acute central nervous system disorders
and the brain specificity of S-100B release was questioned by a
number of investigators, and specificity of NSE and CFAP in ischemic
stroke is not fully demonstrated.
Another limitation is that our study is an observational study
that can only in part suggest whether the biomarkers under dis-
cussion might help to identify such patients at an early, prehospital
stage and this extremely important point requires future recogni-
tion and discussion.
Moreover, our findings are based upon a cohort of patients in
whom the diagnosis is already made owing to the fact that the aim
of our study is to evaluate the association between some laboratory
variables and known stroke diagnosis, but future studies should
evaluate the diagnostic role of these biomarkers in patients with
suspected ischemic stroke, to evaluate the power of the variables
we reported as strictly associated with stroke diagnosis in acute
stroke patients. An interesting question is to evaluate whether these
observations differ from those in patients with hemorrhagic stroke
or alternative acute or chronic neurological conditions.
Only point measurement could be another limitation of the
study since repeated measures may be necessary to define the
variance as well as the predictive nature of a biomarker [33], but
in support of our findings, several studies previously reported
the predictive value of only point measurement of inflammatory
biomarkers in atrial fibrillation [34] and other clinical conditions
such as congestive heart failure [35] acute myocardial infarction
[36] and hypertension [37].
The goal of evaluating the diagnostic role of immuno-
inflammatory and thrombotic–fibrinolytic markers up to 72 h after
symptom onset could further support our only point evaluation.
Lynch et al. [6] reported that four markers are highly correlated
with stroke at 6 and 24 h. These included two markers of inflam-
mation and one marker of thrombosis. Furthermore, the extended
time evolution of TNF- response in humans, peaking at 2–3 days,
sustain our choice to evaluate biomarker plasma levels within 72 h
of symptom onset.
Although there was a demand for neurobiochemical markers,
to date immuno-inflammatory and hemostatic markers could rep-
resent the only possible markers of atherothrombotic mechanisms
with possible diagnostic implications in acute ischemic stroke set-
ting.
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